TITLE

Belmont Hyperthermia Pump in the conduct of intra-operative heated chemotherapy

AUTHOR(S)
Riley, W.
PUB. DATE
March 2009
SOURCE
Perfusion;Mar2009, Vol. 24 Issue 2, p115
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Intra-operative heated chemotherapy (IOHC) has been performed in the Thoracic surgical department of Brigham and Women's Hospital (BWH, Boston, MA, USA) for over a decade. A "home-grown" system was developed for this purpose with limited improvements made to it through the years. This technology is used for neo-adjuvant therapy in the conduct of extra-pleural pneumonectomy and pleurectomy for treatment of mesothelioma. Improvements to the traditional BWH system were sought due to the hazardous nature of the chemotherapy solution and the relative complexity of the IOHC circuit. Belmont Instrument (Belmont Instrument Corporation, Billerica, MA, USA) applied their proprietary infusion/warming technology to develop the Belmontâ„¢ Hyperthermia Pump. The Hyperthermia Pump was designed to recirculate large volumes of fluid while maintaining perfusate temperatures up to 46oC at a flow rate of up to 750 ml/ min. Approval from the FDA for clinical use of this device was granted June 2007. Parameters were defined and investigated to determine if the Hyperthermia Pump would meet or exceed the performance characteristics of the traditional BWH system. Our investigation resulted in the replacement of the traditional BWH circuit. The Belmontâ„¢ Hyperthermia Pump is a compact, easy to use, extremely safe means to deliver intra-operative hyperthermic chemotherapy in the conduct of surgical treatment of mesothelioma.
ACCESSION #
43590251

 

Related Articles

  • Open lung-sparing surgery for malignant pleural mesothelioma: the benefits of a radical approach within multimodality therapy Nakas, Apostolos; Trousse, Delphine Sophie; Martin-Ucar, Antonio E.; Waller, David A. // European Journal of Cardio-Thoracic Surgery;Oct2008, Vol. 34 Issue 4, p886 

    Abstract: Objective: To identify the optimal debulking procedure in patients with malignant pleural mesothelioma who are not suitable for extrapleural pneumonectomy (EPP). Methods: We reviewed 102 consecutive patients (93 male; 9 female, mean age 63 years) who were not suitable for EPP because...

  • Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. W Weder; RA Stahel; J Bernhard; S Bodis; P Vogt; P Ballabeni; D Lardinois; D Betticher; R Schmid; R Stupp; HB Ris; M Jermann; W Mingrone; AD Roth; A Spiliopoulos; On behalf of the Swiss Group for Clinical Cancer Research // Annals of Oncology;Jul2007, Vol. 18 Issue 7, p1196 

    Background: The aim of this multicenter trial was to prospectively evaluate neo-adjuvant chemotherapy followed by extrapleural pneumonectomy (EPP) and radiotherapy, including quality of life as outcome. Patients and methods: Eligible patients had malignant pleural mesothelioma of all...

  • Malignes Pleuramesotheliom. Bölükbas, S.; Schirren, J. // Der Chirurg;Jun2013, Vol. 84 Issue 6, p487 

    The role of surgical resection per se and the type of surgery in the management of multimodality treated malignant pleural mesothelioma remains controversial. Patient selection for either extrapleural pneumonectomy or radical pleurectomy depends not only on the cardiopulmonary status of the...

  • Incidence and management of complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma Opitz, Isabelle; Kestenholz, Peter; Lardinois, Didier; Müller, Michael; Rousson, Valentin; Schneiter, Didier; Stahel, Rolf; Weder, Walter // European Journal of Cardio-Thoracic Surgery;Apr2006, Vol. 29 Issue 4, p579 

    Abstract: Objective: To investigate the incidence and management of postoperative complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma. Methods: Patients with histologically proven mesothelioma of clinical stages T1–3,...

  • Thoracic surgery and interventional procedures.  // Thorax;Dec2005 Supplement 2, Vol. 60, pii46 

    The article presents several abstracts related to thoracic surgery. They include "The Use of Predicted Post Operative Lung Function to Predict Duration of Intensive Care Unit Admission Following Pulmonary Resection for Malignancy," by A. Jha, E.M. Thomson, D.D. Melley, G. Ladas and T.W. Evans,...

  • Pleural Mesothelioma: An Institutional Experience of 66 Cases. Soomin Ahn; In Ho Choi; Joungho Han; Jhingook Kim; Myung-Ju Ahn // Korean Journal of Pathology;Apr2014, Vol. 48 Issue 2, p91 

    Background: Malignant mesothelioma of the pleura is an aggressive tumor known to be associated with asbestos. Histological diagnosis of mesothelioma is challenging and is usually aided by immunohistochemical markers. Methods: During an 18-year period (1995-2012), 66 patients with pleural...

  • Treatment of malignant pleural mesothelioma. Alolayan, Ashwaq; Saadeddin, Ahmed; Bamousa, Ahmed; Jazieh, Abdul-Rahman // Annals of Thoracic Medicine;Mar2010 Supplement, Vol. 5 Issue S, pS71 

    Malignant pleural mesothelioma (MPM) is often treated with combination chemotherapy with a platin compound and a folate antagonist being the recommended treatment of patients with advance disease. Patients with potentially operable MPM can be offered the benefit of a more radical multimodality...

  • Aggressive management under debate. Lee, Christopher W. // Oncology Exchange;Nov2011, Vol. 10 Issue 4, pS:11 

    The article discusses the aggressive management malignant pleural mesothelioma (MPM) disease. It cites a study which raises concerns over the role of extrapleural pneumonectomy (EPP) in treating patients with MPM. It shows that chemotherapy is associated with a modest survival benefit in fit...

  • Commentary on: Belmont Hyperthermia Pump in the conduct of intraoperative heated chemotherapy. Riley, W. // Perfusion;Mar2009, Vol. 24 Issue 2, p119 

    Information about the issues discussed at the 30th Annual Seminar of the American Academy of Cardiovascular Perfusion held in Dallas, Texas from February 5-8, 2009 is presented. Topics includes hypothermia pump in the conduct of intraoperative heated chemotherapy. The event featured several...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics